Metraipolis › archive › dc_6ef7dde39100

HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center Cohort — Europe PMC PMID:42512804

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42512804
DOI
10.3390/medicina62071261
License (as archived)
solo-consultazione
Archived
2026-10-31T06:28:23.576Z
SHA-256 of the archived text
f1c31e12d9682e1ca333d8789440bf9f5a53627d5ec7b92a1f70b5964753019f
Stable URL of this page
https://metraipolis.com/documento/dc_6ef7dde39100

How to cite

HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center Cohort — Europe PMC PMID:42512804 — Europe PMC (en), https://europepmc.org/article/MED/42512804 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6ef7dde39100 (Metraipolis archive dc_6ef7dde39100, sha256 f1c31e12d9682e1ca333d8789440bf9f5a53627d5ec7b92a1f70b5964753019f)
BibTeX
@misc{dc6ef7dde39100,
  title = {HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center Cohort — Europe PMC PMID:42512804},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42512804},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6ef7dde39100; sha256 f1c31e12d9682e1ca333d8789440bf9f5a53627d5ec7b92a1f70b5964753019f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42512804. Agents can read the archived copy with the MCP tool read_document.